These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 7888191)

  • 21. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
    Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
    J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peptide serology for analysis of the inter- and intra-individual variation in the HIV-1 V3 domain.
    Jansson M; Wahren B; Albert J; Scarlatti G; Franzén L; Kataaha PK; Katabira E; Mubiro F; Wigzell H; Rossi P
    AIDS; 1994 Apr; 8(4):413-21. PubMed ID: 8011244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of correlation between V3-loop peptide enzyme immunoassay serologic subtyping and genetic sequencing.
    Nkengasong JN; Willems B; Janssens W; Cheingsong-Popov R; Heyndrickx L; Barin F; Ondoa P; Fransen K; Goudsmit J; van der Groen G
    AIDS; 1998 Aug; 12(12):1405-12. PubMed ID: 9727560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly specific V3 peptide enzyme immunoassay for serotyping HIV-1 specimens from Thailand.
    Pau CP; Lee-Thomas S; Auwanit W; George JR; Ou CY; Parekh BS; Granade TC; Holloman DL; Phillips S; Schochetman G
    AIDS; 1993 Mar; 7(3):337-40. PubMed ID: 8471195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R; Meyer D
    Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pattern of antibody response against the V3 loop in children with vertically acquired immunodeficiency virus type 1 (HIV-1) infection.
    De Rossi A; Zanotto C; Mammano F; Ometto L; Del Mistro A; Chieco-Bianchi L
    AIDS Res Hum Retroviruses; 1993 Mar; 9(3):221-8. PubMed ID: 7682425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. V3 serological subtyping of human immunodeficiency virus type 2 infection is not relevant.
    Plantier JC; Damond F; Souquières S; Brun-Vézinet F; Simon F; Barin F
    J Clin Microbiol; 2001 Oct; 39(10):3803-7. PubMed ID: 11574625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid grouping of HIV-1 infection in subtypes A to E by V3 peptide serotyping and its relation to sequence analysis.
    Sherefa K; Sönnerborg A; Steinbergs J; Sällberg M
    Biochem Biophys Res Commun; 1994 Dec; 205(3):1658-64. PubMed ID: 7811250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1.
    Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D
    Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Presence of multiple genetic subtypes of human immunodeficiency virus type 1 proviruses in Uganda.
    Bruce C; Clegg C; Featherstone A; Smith J; Biryahawaho B; Downing R; Oram J
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1543-50. PubMed ID: 7888209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions.
    Peeters M; Nkengasong J; Willems B; Karita E; Delaporte E; Van den Haesevelde M; Piot P; van der Groen G
    AIDS; 1994 Dec; 8(12):1657-61. PubMed ID: 7888113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distribution of linear antigenic epitopes on GP120 encoded in sibling clones of novel New York HIV-1 subtype B isolates.
    Riley JP; Pestano GA; Harewood K; Alfred LJ; Guyden J; Boto WM
    Cell Mol Biol (Noisy-le-grand); 1995; 41 Suppl 1():S83-91. PubMed ID: 8574151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preliminary results of V3 loop peptide-primary neutralizing domain conjugate phase 1 vaccine trail.
    Rubinstein A; Goldstein H; Pettoello-Mantovani M; Cryz SJ
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S149-53. PubMed ID: 7865291
    [No Abstract]   [Full Text] [Related]  

  • 36. Seroreactivity to HIV-1 V3 subtypes A to H peptides of Argentinian HIV-positive sera.
    Devito C; Levi M; Hinkula J; Fernandez Medina RD; Libonatti O; Wigzell H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Feb; 17(2):156-9. PubMed ID: 9473017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Molecular analysis of the principal neutralization epitope (V3 loop) of human immunodeficiency virus type 1 in Argentina].
    Gómez Carrillo M; Piccardo C; Libonatti O
    Rev Argent Microbiol; 1992; 24(2):91-101. PubMed ID: 1298019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serotyping HIV-1 with V3 peptides: detection of high avidity antibodies presenting clade-specific reactivity.
    Casseb J; Katzenstein D; Winters M; Brigido LF; Duarte AJ; Hendry RM
    Braz J Med Biol Res; 2002 Mar; 35(3):369-75. PubMed ID: 11887216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High specificity of V3 serotyping among human immunodeficiency virus type-1 subtype C infected patients with varying disease status and viral phenotype.
    Walker PR; Cilliers T; Choge IA; Taylor N; Cohen SS; Morris L
    J Med Virol; 2006 Oct; 78(10):1262-8. PubMed ID: 16927278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.